TrialPharmaceutical research2022

A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose.

Tair Lapidot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.